252 related articles for article (PubMed ID: 25959529)
1. Effect of pioglitazone on plasma ceramides in adults with metabolic syndrome.
Warshauer JT; Lopez X; Gordillo R; Hicks J; Holland WL; Anuwe E; Blankfard MB; Scherer PE; Lingvay I
Diabetes Metab Res Rev; 2015 Oct; 31(7):734-44. PubMed ID: 25959529
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic Effects of Low-Dose Pioglitazone in Patients with the Metabolic Syndrome without Diabetes Mellitus.
Vu A; Kosmiski LA; Beitelshees AL; Prigeon R; Sidhom MS; Bredbeck B; Predhomme J; Deininger KM; Aquilante CL
Pharmacotherapy; 2016 Mar; 36(3):252-62. PubMed ID: 26822630
[TBL] [Abstract][Full Text] [Related]
3. Chronic treatment with pioglitazone does not protect obese patients with diabetes mellitus type II from free fatty acid-induced insulin resistance.
Serlie MJ; Allick G; Groener JE; Ackermans MT; Heijligenberg R; Voermans BC; Aerts JM; Meijer AJ; Sauerwein HP
J Clin Endocrinol Metab; 2007 Jan; 92(1):166-71. PubMed ID: 17062758
[TBL] [Abstract][Full Text] [Related]
4. Plasma ceramides are elevated in female children and adolescents with type 2 diabetes.
Lopez X; Goldfine AB; Holland WL; Gordillo R; Scherer PE
J Pediatr Endocrinol Metab; 2013; 26(9-10):995-8. PubMed ID: 23612696
[TBL] [Abstract][Full Text] [Related]
5. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.
Sharma PK; Bhansali A; Sialy R; Malhotra S; Pandhi P
Clin Endocrinol (Oxf); 2006 Dec; 65(6):722-8. PubMed ID: 17121522
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic effects of rosiglitazone in nondiabetic patients with metabolic syndrome.
Aquilante CL; Kosmiski LA; Zineh I; Rome LC; Knutsen SD
Pharmacotherapy; 2010 Mar; 30(3):236-47. PubMed ID: 20180607
[TBL] [Abstract][Full Text] [Related]
7. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
Miyazaki Y; Mahankali A; Wajcberg E; Bajaj M; Mandarino LJ; DeFronzo RA
J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
[TBL] [Abstract][Full Text] [Related]
8. Genetic Variants Associated with Elevated Plasma Ceramides in Individuals with Metabolic Syndrome.
Lee S; Kim SA; Kim Y; Kim J; Hong G; Hong J; Choi K; Eom CS; Baik S; Lee MK; Lee KR
Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011408
[TBL] [Abstract][Full Text] [Related]
9. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
10. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
[TBL] [Abstract][Full Text] [Related]
11. Diet/Exercise versus pioglitazone: effects of insulin sensitization with decreasing or increasing fat mass on adipokines and inflammatory markers.
Shadid S; Stehouwer CD; Jensen MD
J Clin Endocrinol Metab; 2006 Sep; 91(9):3418-25. PubMed ID: 16804048
[TBL] [Abstract][Full Text] [Related]
12. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus.
Teranishi T; Ohara T; Maeda K; Zenibayashi M; Kouyama K; Hirota Y; Kawamitsu H; Fujii M; Sugimura K; Kasuga M
Metabolism; 2007 Oct; 56(10):1418-24. PubMed ID: 17884455
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome.
Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Piccinni MN; Fogari E; Salvadeo S; Ciccarelli L; Fogari R
Diabetes Res Clin Pract; 2005 Jul; 69(1):5-13. PubMed ID: 15955382
[TBL] [Abstract][Full Text] [Related]
14. Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance.
Haus JM; Kashyap SR; Kasumov T; Zhang R; Kelly KR; Defronzo RA; Kirwan JP
Diabetes; 2009 Feb; 58(2):337-43. PubMed ID: 19008343
[TBL] [Abstract][Full Text] [Related]
15. Serum sphingolipids: relationships to insulin sensitivity and changes with exercise in humans.
Bergman BC; Brozinick JT; Strauss A; Bacon S; Kerege A; Bui HH; Sanders P; Siddall P; Kuo MS; Perreault L
Am J Physiol Endocrinol Metab; 2015 Aug; 309(4):E398-408. PubMed ID: 26126684
[TBL] [Abstract][Full Text] [Related]
16. Improved insulin sensitivity after exercise training is linked to reduced plasma C14:0 ceramide in obesity and type 2 diabetes.
Kasumov T; Solomon TP; Hwang C; Huang H; Haus JM; Zhang R; Kirwan JP
Obesity (Silver Spring); 2015 Jul; 23(7):1414-21. PubMed ID: 25966363
[TBL] [Abstract][Full Text] [Related]
17. The effect of pioglitazone on the liver: role of adiponectin.
Gastaldelli A; Miyazaki Y; Mahankali A; Berria R; Pettiti M; Buzzigoli E; Ferrannini E; DeFronzo RA
Diabetes Care; 2006 Oct; 29(10):2275-81. PubMed ID: 17003306
[TBL] [Abstract][Full Text] [Related]
18. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study.
Wallace TM; Levy JC; Matthews DR
Diabet Med; 2004 Jun; 21(6):568-76. PubMed ID: 15154941
[TBL] [Abstract][Full Text] [Related]
19. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.
Berria R; Gastaldelli A; Lucidi S; Belfort R; De Filippis E; Easton C; Brytzki R; Cusi K; Jovanovic L; DeFronzo R
Clin Pharmacol Ther; 2006 Aug; 80(2):105-14. PubMed ID: 16890572
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes.
Tonelli J; Li W; Kishore P; Pajvani UB; Kwon E; Weaver C; Scherer PE; Hawkins M
Diabetes; 2004 Jun; 53(6):1621-9. PubMed ID: 15161771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
